UK Plans For Robust Life Sciences Regulation Post-Brexit

Published date13 November 2020
Subject MatterLife Sciences,UK Bribery Act,EU,Civil Monetary Penalty,Corporate Crimes,UK Brexit,Medicines and Healthcare Products Regulatory Agency (MHRA)
AuthorWolfgang Schönig,Gareth Rees QC
Law FirmMorrison & Foerster LLP

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT